Making Bladder Cancer Cells Glow earns French Biotech €1.5M

22/02/2016 - 3 minutes

VitaDX (France), is developing a non-invasive medical device for early detection of bladder cancer, based on a syndicate of French academic research. This simple urine sample analysis has attracted over €1.5M in preparation for clinical trials and a global market launch.

vitadx_bladder_cancer_diagnostics_cnrsThe technology operated by VitaDX is the result of a research collaboration between the Institute of Molecular Sciences of Orsay (ISMO) which is a CNRS at the University of South Paris, and the Kremlin-Bicêtre Hospital (also in Paris).

VitaDX has also received financial support from the French tech transfer office SATT Paris-Saclay for its development, which enabled the establishment of a partnership with the French Aerospace Lab.

Conventional diagnostic tests for bladder cancer use cell microscopy from urine sample using a Papanicolaou stain – a technique which lacks sensitivity for early cancers (an average of just 20% sensitivity). This is because the cell’s morphology is not yet altered for a proper diagnosis to be possible.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member